Dr Reddy's Laboratories Announces the Launch of
Abiraterone Acetate Tablets USP
News Desk, News Nation 360 : Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr Reddy’s”) announced the launch of Abiraterone Acetate Tablets USP, 250 mg, a therapeutic equivalent generic version of Zytiga® (abiraterone acetate) approved by the U.S. Food and Drug Administration (USFDA). Dr Reddy’s Abiraterone Acetate is available in 250 mg tablets in bottle count sizes of 120. The Zytiga® brand and the generic market had U.S. sales of approximately $454 million MAT for the most recent twelve months ending in March 2020 according to IQVIA Health.
Report : Anustup Kundu